Company Overview and News

 
Balaji Telefilms Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-09-06 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BALAJITELE 532382

 
Balaji Telefilms Limited - Press Release

2018-09-03 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BALAJITELE 532382

 
Balaji Telefilms appoints Aashish Singh as CEO of movie business

2018-09-03 moneycontrol
Balaji Telefilms Monday said it has appointed Aashish Singh as Chief Executive Officer (CEO) of its movie business. "Aashish will have overall business responsibility for the movie business and will be reporting to Nachiket Pantvaidya, Group Chief Operating Officer," Balaji Telefilms said in a BSE filing.
BALAJITELE 532382

 
Balaji Telefilms Limited - Shareholders meeting

2018-09-01 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BALAJITELE 532382

 
Balaji Telefilms Limited - Shareholders meeting

2018-08-31 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BALAJITELE 532382

 
Jabariya Jodi: Playing a Bihari boy will be very different, says Sidharth Malhotra

2018-08-23 freepressjournal.in
Mumbai: Actor Sidharth Malhotra knows “Jabariya Jodi” will be a unique experience for him as it will require him to exude the aura of a typical Bihari person. From playing a college student in his first movie “Student of the Year”, to a rough and a hardened criminal in “Brothers”, the actor has experimented with roles. But a first look of “Jabariya Jodi” has assured fans that the actor is set to serve up a different and desi flavour with his new film.
BALAJITELE 532382

 
Airtel and ZEE Entertainment sign up for content alliance

2018-08-20 livemint
New Delhi: Telecommunications company Bharti Airtel has announced a strategic content partnership with media and entertainment firm Zee Entertainment Enterprises Ltd (ZEEL) to “drive the over-the-top video streaming ecosystem in India”.
BALAJITELE 532454 ZEEEY 532382 505537 BHRQY BHARTIARTL ZEEL

 
Balaji Telefilms Limited - Updates

2018-08-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BALAJITELE 532382

 
Sidharth Malhotra, Parineeti Chopra escalate from ‘Shotgun Shaad’ to ‘Jabariya Jodi’

2018-08-10 freepressjournal.in
Post giving a hit movie Hasee to Phasee, fans are excited as Parineeti Chopra and Sidharth Malhotra reunite for another project. Earlier, it was reported that the duo will be seen in Shotgun Shaadi but the makers have decided to re-christen it as Jabariya Jodi. The film revolves around a love story based on the concept of groom kidnapping, as per a report by DNA.
BALAJITELE 532382

 
Balaji Telefilms Limited - Updates

2018-08-09 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BALAJITELE 532382

 
Balaji Telefilms Limited - AGM/Book Closure

2018-08-08 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BALAJITELE 532382

 
Balaji Telefilms Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-08-08 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BALAJITELE 532382

 
Friendship Day 2018: Why aren’t these 10 pairs of Bollywood celebrities BFFs yet?

2018-08-04 freepressjournal.in
Friendship Day is around the corner with another year of colourful bands, exchanging gifts and making memories. While some of us have our predetermined squad that is inseparable, it might not be harmful to delve into building new bonds with someone you could have never imagined. Our judgements are existing notions about a person could serve as an unhealthy way of pursuing relationships, of which Bollywood is no angel either.
BALAJITELE 532382

 
WOW! Priyanka Chopra, Salman Khan, Karan Johar and 9 other Indians make it to Variety’s 500 influential leaders in entertainment

2018-07-23 freepressjournal.in
Every year, the coveted magazine Variety unveils the world’s 500 most influential business leaders who are shaping the global $2 trillion entertainment industry. The list is updated annually and features the accomplishments of the business leaders in the past 12 months. This year, the list includes 12 Indian faces from the entertainment industry including Salman Khan, Priyanka Chopra, Karan Johar, Aditya Chopra, Ekta Kapoor amongst others.
BALAJITELE 500325 ZEEEY 532382 RELIANCE RIGD 505537 ZEEL RLNIY

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

10h - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

10h - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

12h - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...